Today's Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics

 Today's Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and
                              Cell Therapeutics

PR Newswire

LONDON, March 6, 2013

LONDON, March 6, 2013 /PRNewswire/ --

On Tuesday, the markets retained their bullish mode as indices created yet
another life-time high. The markets showed across the board improvement, and
the Healthcare sector saw Johnson & Johnson creating a new all time high. The
Dow Jones ended its latest session at 14,253.77, up 0.89 percent while NASDAQ
was up 1.32 percent to close at 3,224.13. Similarly, S&P closed on a positive
note at 1,539.79, up 0.96 percent. Our research team took a look at the
Healthcare sector, focusing on the biotech Industry which includes major
companies like PDL BioPharma Inc. (NASDAQ: PDLI), Dendreon Corporation
(NASDAQ: DNDN), Medivation Inc. (NASDAQ: MDVN), ACADIA Pharmaceuticals Inc.
(NASDAQ: ACAD) and Cell Therapeutics Inc. (NASDAQ: CTIC). StockCall
professionals have completed their technical analysis on PDLI, DNDN, MDVN,
ACAD and CTIC and these free reports are accessible by registering at

http://www.stockcall.com/research 

On top of ending its previous trading session flat, PDL BioPharma Inc. is
still down 0.85 percent for the year. However, the stock has grown 6.16
percent in the past 52 weeks. PDLI closed flat at $6.98 on volume of 2.56
million shares on Tuesday. Its average trading volume stands at 2.01 million
shares. PDL BioPharma's shares currently face resistance at around $7.04. The
stock has support at around $6.89. It is currently trading above its 20-day,
but below 50-day moving averages, which is a neutral signal. Sign up for the
free technical research on PDLI at

http://www.StockCall.com/PDLI030613.pdf

Dendreon Corporation traded in the range of $5.61 and $5.85 during Tuesday's
trading session. It opened at $5.75 and closed at $5.70, down 0.35 percent.
The stock is currently in a neutral mode and has its first resistance level at
$5.80. Upon breaching this level, the company may go as high as $6.03. It
traded 3.47 million shares and is above its 20-day moving average price. Its
first support level is at $5.42. So far in 2013, the stock is up 7.75 percent.
Be sure to read our latest technical research on DNDN by registering at

http://www.StockCall.com/DNDN030613.pdf

Despite the upward movement shown by broad market indices, Medivation Inc.'s
stock finished 2.47 percent lower at $45.86, with volume up from daily average
of 1.50 million to 3.64 million. The biotech company's stock is down so far in
2013 with a year-to-date decline at 10.36 percent. However, the stock
currently shows a bearish trend which is further confirmed by the stock's MACD
chart. Medivation has its first support level at $43.26. In the coming trading
sessions, the stock is likely to go as high as $49.09. Sign up and read the
complimentary report on MDVN at

http://www.StockCall.com/MDVN030613.pdf

ACADIA Pharmaceuticals Inc.'s stock rose mildly in its latest trading session.
The stock closed 0.63 percent higher at $6.37 with 1.48 million share volume.
Despite the mild upward movement, the stock is still up more than 36 percent
for the year. In the past 52 weeks, the company's stock is up 300 percent. The
stock currently has support at $6.28 level. The stock's MACD chart shows a
neutral trend. ACADIA may face its first resistance level at $6.75. Upon
breaching this level, the stock may go as high as $7.03. The free report on
ACAD can be downloaded by signing up now at

http://www.StockCall.com/ACAD030613.pdf

Shares of Cell Therapeutics Inc. ended flat in Tuesday's trading session. The
stock closed at $1.26 on below average volume of 966,000 shares. The company's
shares have lost more than 3 percent this year, underperforming the broad
market. It has support at $1.15. Despite the flat ending, Cell Therapeutics'
shares are still trading below their 50-day and 200-day moving averages. Free
report on CTIC can be accessed by registering at

http://www.StockCall.com/CTIC030613.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com 

SOURCE StockCall.com

Contact: Contact Person: William T. Knight, Email: info@stockcall.com, Contact
Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)
 
Press spacebar to pause and continue. Press esc to stop.